Showing results (21-30 of 58) with videos related to
Sort By:
Pageof 6
Leukemia & Lymphoma|July 25, 2022
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United StatesKaran L Chohan, Jithma P Abeykoon, Stephen M Ansell, et al.Blood|September 29, 2018
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphomaHan W Tun, Patrick B Johnston, Lisa M DeAngelis, et al.British Journal of Haematology|November 19, 2013
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemiaAneel Paulus, Kasyapa Chitta, Sharoon Akhtar, et al.Blood|October 28, 2017
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trialNancy L Bartlett, Brian A Costello, Betsy R LaPlant, et al.Leukemia Research|May 15, 2012
Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phaseChad Cherington, James L Slack, Jose Leis, et al.Anti-Cancer Drugs|April 17, 2023
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myelomaMuhamad Alhaj Moustafa, Ricardo Parrondo, Mays F Abdulazeez, et al.Leukemia & Lymphoma|October 15, 2020
Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemiaMadugodaralalage D S K Gunaratne, Alexander J Sahakian, Jithma P Abeykoon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II studyGrzegorz S Nowakowski, Betsy LaPlant, William R Macon, et al.British Journal of Haematology|November 24, 2011
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myelomaMeaghan L Khan, Craig B Reeder, Shaji K Kumar, et al.American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.Pageof 6